Dutasteride is marketed under the brand name Avodart [1].
When did Avodart first receive approval?
Avodart was approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate [2].
What is Avodart used to treat?
Avodart is prescribed to treat an enlarged prostate, also known as symptomatic benign prostatic hyperplasia (BPH), in men. It helps to shrink the prostate gland and relieve urinary symptoms associated with BPH [1][2].
How does Avodart work?
Avodart is a 5-alpha-reductase inhibitor. It works by blocking the production of a hormone called dihydrotestosterone (DHT) [1]. DHT is a key factor in the growth of the prostate gland. By reducing DHT levels, Avodart helps to shrink the prostate and alleviate symptoms of BPH [1][2].
What is the difference between dutasteride and finasteride?
Both dutasteride and finasteride are 5-alpha-reductase inhibitors used to treat BPH. However, dutasteride inhibits two types of the 5-alpha-reductase enzyme, while finasteride inhibits only one type. This difference means dutasteride is generally more potent at lowering DHT levels than finasteride [3]. Finasteride is also marketed under the brand name Proscar for BPH [4].
What are the potential side effects of Avodart?
Common side effects of Avodart can include sexual dysfunction, such as decreased libido, erectile dysfunction, and ejaculation disorders [1]. Other potential side effects may involve breast tenderness or enlargement, and allergic reactions [1].
When does the patent for Avodart expire?
Information regarding the specific patent expiration dates for Avodart can be found on resources like DrugPatentWatch.com [5]. Patent exclusivity is crucial for brand-name drug manufacturers, and its expiration often opens the door for generic competition.
Can generic versions of Avodart be sold before patent expiry?
Generally, generic versions of a drug cannot be sold until the relevant patents and exclusivity periods have expired. Challenges to patents or specific legal settlements can sometimes alter these timelines, but the standard pathway involves waiting for patent expiry [5].
Where can I find more information about Avodart and its patents?
Detailed information on Avodart, including its patent status and potential for generic entry, is available through specialized databases and resources. DrugPatentWatch.com provides comprehensive data on pharmaceutical patents and exclusivity [5].
Who manufactures Avodart?
Avodart is manufactured by GlaxoSmithKline [1].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.fda.gov/
3. https://www.ncbi.nlm.nih.gov/
4. https://www.mayoclinic.org/
5. https://www.drugpatentwatch.com/